| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
207,851,000 |
| Market
Cap: |
11.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.86 - $59.82 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
| Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
| Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
| Total People Sold |
1 |
1 |
12 |
18 |
| Total Sell Transactions |
1 |
1 |
25 |
69 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2023-08-01 |
4 |
S |
$46.64 |
$13,171 |
D/D |
(276) |
17,516 |
|
19% |
|
| Ferraro Joseph Anthony |
SVP, General Counsel, CCO |
• – – |
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,145 |
5,145 |
|
- |
|
| Hunt Patricia |
Pres. Consumer Health Div |
• – – |
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,952 |
11,106 |
|
- |
|
| Hunt Patricia |
Pres. Consumer Health Div |
• – – |
2023-08-01 |
4 |
S |
$47.95 |
$7,720 |
D/D |
(161) |
9,154 |
|
19% |
|
| Hopson Ricky |
Pres. Clinical Dev Supply Div |
• – – |
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,790 |
21,047 |
|
- |
|
| Hopson Ricky |
Pres. Clinical Dev Supply Div |
• – – |
2023-08-01 |
4 |
S |
$47.86 |
$9,333 |
D/D |
(195) |
16,257 |
|
19% |
|
| Zayas Ricardo |
SVP, Operations, Biologics NA |
• – – |
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,435 |
6,223 |
|
- |
|
| Maselli Alessandro |
President & CEO |
• • – |
2023-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
46,396 |
87,586 |
|
- |
|
| Masanovich Matti |
SVP, Chief Financial Officer |
• – – |
2023-07-05 |
4 |
A |
$0.00 |
$0 |
D/D |
36,864 |
36,864 |
|
- |
|
| Carroll J Martin |
Director |
– • – |
2023-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
555 |
21,078 |
|
- |
|
| Gargiulo Mario |
SVP, Ops, Biologics Europe |
• – – |
2023-05-01 |
4 |
S |
$49.86 |
$33,805 |
D/D |
(678) |
5,676 |
|
3% |
|
| Boerman Manja |
Pres. BioModalities Division |
• – – |
2023-05-01 |
4 |
S |
$49.86 |
$72,098 |
D/D |
(1,446) |
14,414 |
|
3% |
|
| Zayas Ricardo |
SVP, Operations, Biologics NAO |
• – – |
2023-01-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,788 |
|
-25% |
|
| Hopson Ricky |
Pres. Clinical Dev Supply Div |
• – – |
2023-01-23 |
4 |
S |
$49.36 |
$31,738 |
D/D |
(643) |
16,452 |
|
30% |
|
| Boerman Manja |
Pres. BioModalities Division |
• – – |
2022-12-05 |
4 |
S |
$51.70 |
$40,326 |
D/D |
(780) |
15,860 |
|
11% |
|
| Grippo Michael J |
SVP, Strategy & Corp. Dev. |
• – – |
2022-10-31 |
4 |
S |
$65.83 |
$161,349 |
D/D |
(2,451) |
17,792 |
|
-7% |
|
| Carroll J Martin |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
20,523 |
|
- |
|
| Barber Michael J |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
6,396 |
|
- |
|
| Kreuzburg Christa |
Director |
– • – |
2022-10-27 |
4 |
D |
$66.27 |
$27,900 |
D/D |
(421) |
13,058 |
|
- |
|
| Kreuzburg Christa |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
13,479 |
|
- |
|
| Zippelius Peter |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
11,979 |
|
- |
|
| Balachandran Madhavan |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
20,448 |
|
- |
|
| Lucier Gregory T |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
25,258 |
|
- |
|
| Crane Rosemary A |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
16,880 |
|
- |
|
| Stahl Jack L |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,149 |
36,328 |
|
- |
|
821 Records found
|
|
Page 5 of 33 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.33 (0.58%) 
